HYOU1 and cancer: GRP170, on the other hand, although the least studied chaperone with regards to cancer diagnosis and prognosis, is gaining attention in cancer therapy due to its immunoadjuvant activity as it is capable of inducing both innate and adaptive immune responses [113,114].